DUBLIN, December 08, 2021--(BUSINESS WIRE)--The "Global Psychiatry Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Psychiatry dealmaking in the biopharma industry since 2014
Analysis of Psychiatry deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Psychiatry deal contract documents
Comprehensive access to over 780 Psychiatry deal records
The leading Psychiatry deals by value since 2014
Most active Psychiatry dealmakers since 2014
Global Psychiatry Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.
The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.
In Global Psychiatry Partnering 2014 to 2021, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Psychiatry Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 780 psychiatry deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Psychiatry Partnering 2014 to 2021 provides the reader with the following key benefits:
In-depth understanding of Psychiatry deal trends since 2014
Access Psychiatry deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Psychiatry partner companies
Comprehensive access to over 780 links to actual Psychiatry deals entered into by the world's biopharma companies
In-depth review of Psychiatry deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Psychiatry opportunities
Uncover companies actively partnering Psychiatry opportunities
Academic Drug Discovery Consortium
Advanced Cooling Therapy
Advocate Health Care
Aelan Cell Technologies
Air Force General Hospital
Akili Interactive Labs
Allen Institute for Brain Science
Allergan (name changed from Actavis)
Alzheimer's Drug Discovery Foundation
Alzheimer's Foundation of America
Alzheimer's Research UK
Alzheimer Society Research
Alzheimers Research UK
American Diabetes Association
American Heart/Stroke Association
American Sleep Apnea Association
Analytical Testing Laboratory
Anavex Life Sciences
ARCH Personalized Medicine Initiative
Arizona State University
Association for Frontotemporal Degeneration
Assuta Medical Centers
ATAI Life Sciences
and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/d6xvv9
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005608/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900